Trademark Trial and Appeal Board Electronic Filing System. http://estta.uspto.gov
`ESTTA786390
`12/01/2016
`
`ESTTA Tracking number:
`
`Filing date:
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`Notice of Opposition
`
`Notice is hereby given that the following party opposes registration of the indicated application.
`
`Opposer Information
`
`Name
`
`Iroko Properties Inc.
`
`Granted to Date
`of previous ex-
`tension
`
`Address
`
`Attorney informa-
`tion
`
`01/11/2017
`
`Geneva Place, Waterfront Drive
`Roadtown, Tortola,
`VIRGIN ISLANDS, BRITISH
`
`Keith Barritt
`Fish & Richardson P.C.
`P.O. Box 1022
`Minneapolis, MN 55440-1022
`UNITED STATES
`tmdoctc@fr.com, barritt@fr.com Phone:202-783-5070
`
`Applicant Information
`
`Application No
`
`86767040
`
`Publication date
`
`09/13/2016
`
`Opposition Filing
`Date
`
`Applicant
`
`12/01/2016
`
`Opposition Peri-
`od Ends
`
`01/11/2017
`
`Acorda Therapeutics, Inc
`420 Saw Mill River Road
`Ardsley, NY 10502
`UNITED STATES
`
`Goods/Services Affected by Opposition
`
`Class 005. First Use: 0 First Use In Commerce: 0
`All goods and services in the class are opposed, namely: pharmaceutical and biological preparations
`used in the treatment of neurological diseases, disorders or conditions
`
`Grounds for Opposition
`
`Priority and likelihood of confusion
`
`Trademark Act Section 2(d)
`
`Mark Cited by Opposer as Basis for Opposition
`
`U.S. Registration
`No.
`
`4505759
`
`Registration Date
`
`04/01/2014
`
`Word Mark
`
`ZORVOLEX
`
`Application Date
`
`09/01/2011
`
`Foreign Priority
`Date
`
`NONE
`
`

`
`Design Mark
`
`Description of
`Mark
`
`Goods/Services
`
`NONE
`
`Class 005. First use: First Use: 2013/12/18 First Use In Commerce: 2013/12/18
`Pharmaceutical preparations for the treatment of pain and pain associated with
`inflammation
`
`Attachments
`
`85413540#TMSN.png( bytes )
`zorbimax opp.pdf(737854 bytes )
`
`The undersigned hereby certifies that a copy of this paper has been served upon all parties, at their address
`record by First Class Mail on this date.
`
`Certificate of Service
`
`Signature
`
`Name
`
`Date
`
`/Keith Barritt/
`
`Keith Barritt
`
`12/01/2016
`
`

`
`IN T i "E UNITE ) STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`In the matter of application Serial No. 86767040
`For the mark ZORBIVIAX
`Jublished in the Official Gazette on September 13, 2016
`
`IROKO PROPERTIES lNC.,
`
`Opposer,
`
`V.
`
`ACORDA THERAPEUTICS, INC.
`
`Applicant.
`
`OPPOSITION NO.
`
`NOTICE OF OPPOSITION
`
`Iroko Properties Inc. (“Iroko” or “Opposer”), a company of the British
`
`_ Virgin Islands with a business address of Geneva Place, Waterfront Drive, Roadtovvn,
`
`Tortola, British Virgin Islands, believes that it will be damaged by registration of the mark
`
`shown in the above-identified application, and hereby opposes such application. Pursuant to
`
`Section 206.03 of the Trademark Trial and Appeal Board, Opposer notes that its business
`
`entity type was mistakenly identified as a “corporation” rather than “company” in its request
`
`for an extension of time to oppose. There is no change in the actual identity of the Opposer.
`
`

`
`The grounds for opposition are as follows:
`
`1.
`
`Iroko owns the trademark ZORVOL_X in the United States and exercises quality
`
`control over the manufacturing of pharmaceuticals sold under the ZORVOLEX trademark.
`
`2.
`
`Iroko owns U.S. trademark registration no. 4,505,759 for ZORVOLEX for
`
`“pharmaceutical preparations for the treatment of pain and pain associated with
`
`inflammation.”
`
`3.
`
`A copy of the ZORVOLEX trademark registration from the electronic database
`
`records of the U.S. Patent and Trademark Office showing the current status and title of the
`
`registration is enclosed as Exhibit 1, pursuant to Section 704.03(b)(l)(A) of the Trademark
`
`Trial and Appeal Board Manual of Procedure.
`
`4.
`
`The ZORVOLEX mark is in use in U.S. commerce, as shown in Exhibit 2.
`
`5.
`
`The ZORVOLEX application that matured into the ZORVOLEX registration has a
`
`filing date of September 1, 2011.
`
`6.
`
`The ZORVOLEX mark was first used in commerce at least as early as
`
`December 18, 2013.
`
`

`
`7.
`
`The ZORBTMAX application, based on a bona fide intent to use the mark, has a
`
`filing date of September 24, 2015.
`
`8.
`
`The goods covered by the ZORBIMAX application are “pharmaceutical and
`
`biological preparations used in the treatment of neurological diseases, disorders or
`
`conditions.”
`
`9.
`
`There are no limits on the channels of trade for the goods in either the ZORBIMAX
`
`application or ZORVOLEX registration.
`
`10.
`
`In the absence of a limitation on the channels of trade, the goods in the ZORBIMAX
`
`application and ZORVOLEX registration are presumed to travel in all normal channels of
`
`trade for such goods.
`
`11.
`
`The goods covered by the ZORBIMAX application are related to the goods covered
`
`by the ZORVOLEX registration.
`
`12.
`
`The ZORBIMAX mark and ZORVOLEX mark share the same ZOR- formative.
`
`13.
`
`The ZORBIMAX mark and ZORVOLEX mark share the same X ending sound.
`
`14.
`
`The ZORBHVIAX mark and ZORVOLEX mark each have three syllables.
`
`

`
`15.
`
`Pharmacists typically Write the beginning letters of a prescription with more care
`
`than the ending letters.
`
`16.
`
`ZORBIMAX may be misread by pharmacists as instructions to dispense
`
`ZORVOLEX.
`
`17.
`
`ZORVOLEX may be misread by pharmacists as instructions to dispense
`
`ZORBIMAX.
`
`18.
`
`ZORVOLEX and ZORBIMAX may be confused by consumers even in the absence
`
`of written prescriptions to pharmacists.
`
`19.
`
`Because of the heightened risk of harm if the Wrong medication is taken, there is
`
`greater scrutiny given to pharmaceutical trademarks than for other marks.
`
`Count 1 — Likelihood of Confusion
`
`20.
`
`Upon information and belief, Applicant cannot claim any rights in ZORBIMAX
`
`prior to September 1, 2011.
`
`21.
`
`Upon information and belief, Applicant cannot claim any rights in ZORB]MAX
`
`prior to December 18, 2013.
`
`

`
`22.
`
`Opposer has priority over the ZOR %IMAX application by Virtue of Opposer’s prior
`
`filing of its ZORVOLEX application and prior use of ZORVOLEX.
`
`23.
`
`The goods identified in the ZORBIMAX application are related to the goods
`
`identified in the ZORVOLEX registration.
`
`24.
`
`In View of Opposer’s prior use of ZORVOLEX for pharmaceuticals, consumers are
`
`likely to be confused that the goods covered by the ZORBIMAXA application emanate
`
`from the same source or are otherwise affiliated with or endorsed by Opposer.
`
`25.
`
`Applicant’s ZORBIMAX mark so resembles Opposer’s previously adopted and
`
`registered ZORVOLEX mark in sight, sound, and overall commercial impression as to be
`
`likely, when used on or in connection with the goods of Applicant, to cause confusion, or to
`
`cause mistake, or to deceive under Section 2(d) of the Lanham Act.
`
`WHEREFORE, Opposer prays that this opposition be sustained and that
`
`Applicant be denied registration of the mark depicted in the ZORBIMAX application.
`
`

`
`Respectfully submitted,
`
`Iroko Properties Inc.
`
`
`,1, V;
`I
`I» V CI’:/Mar“ 3
`
`
`.
`5» «'1.
`
`.
`
`Keith A. Ranifi, Esq.
`FISH & RICHARDSON, P.C.
`P.O. Box 1022
`
`Minneapolis, MN 55440-1022
`Phone: (202) 783-5070
`Fax: (202) 783-2331
`Email:
`tmdoctc@fr.com, barritt@fr.com
`Attorneys for Opposer
`
`December 1, 2016
`
`

`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`3 LFORE T ‘I E TRADEMA, K T AL AND APPEAL BOARD
`
`In the matter of application Serial No. 86767040
`For the mark ZOR %IMAX
`
`Published in the Official Gazette on September 13, 2016
`
`IROKO PROPERTIES INC.,
`
`Opposer,
`
`V.
`
`ACORDA THERAPEUTICS, INC.
`
`Applicant.
`
`OPPOSITION NO.
`
`CERTIFICATE OF SERVICE
`
`In accordance with 37 CFR 2.1l1(b), the undersigned hereby certifies that on
`December 1, 2016, a true copy of the foregoing NOTICE OF OPPOSITION was
`deposited in the U.S. mail, first-class, postage prepaid, addressed to the following counsel
`of record for Acorda Therapeutics, Inc.:
`
`Joseph C. Guagliardo
`Pepper Hamilton LLP
`18th And Arch Streets
`
`3000 Two Logan Square
`Philadelphia, PA 19103
`
`Signature
`
`

`
`
`

`
`Trademark Electronic Search System (TESS)
`
`Page 1 of 2
`
`United States Patent and Trademark Office
`
` Home I Site IndexISearch I FAQ IGlossary I GuidesIContacts I eBusiness I eBiz alerts I Newsl Help
`
`Trademarks > Trademark Electronic Search System (TESS)
`
`TESS was last updated on Wed Oct 12 03:21:07 EDT 2016
`
`NEWER Srrmtwrfiv
`
`"
`
`'
`
`-
`
`Please ogout when you are done to release system resources allocated for you.
`
`Hm»
`
`'
`
`List At: :I OR
`
`to record: I:I Recofd 3 out Of 3
`
`
`
`
`return to TSS)
`
`-ll
`
`'~.n..m--.
`
`I ( Use the "Back" button of the Internet Browser to
`
`ZOVOLE
`
`
`
`Word Mark
`
`ZORVOLEX
`
`Goods and Services
`
`IC 005. US 006 O18 044 046 O51 052. G & S: Pharmaceutical preparations for the treatment
`of pain and pain associated with inflammation. FIRST USE: 20131218. FIRST USE IN
`COMMERCE: 20131218
`
`Standard Characters
`Claimed
`
`Mark Drawing Code
`Serial Number
`
`(4) STANDARD CHARACTER MARK
`85413540
`
`Filing Date
`Current Basis
`
`September 1, 2011
`1A
`
`1B
`Original Filing Basis
`February 14, 2012
`(':‘I'£I;:I‘t‘i’;'nf°'
`Registration Number 4505759
`International
`Registration Number 1091860
`Registration Date
`April 1, 2014
`
`Owner
`
`(REGISTRANT) IROKO PROPERTIES INC. CORPORATION BR.VIRGIN ISLANDS
`GENEVA PLACE, WATERFRONT DRIVE ROADTOWN, TORTOLA BR.V|RGIN ISLANDS
`
`A5SI9“"‘e'“
`Recorded
`
`ASSIGNMENT RECORDED
`
`Attorney of Record
`
`Keith Barritt
`
`Type of Mark
`
`TRADEMARK
`
`http://tmsearch.uspto.gov/bin/showfieid?f:doc&state:Jn8O+:h5u3yp.2.3
`
`10/ 12/20 16
`
`

`
`Trademark Electronic Search System ‘FSS)
`
`Page 2 of 2
`
`PRINCIPAL
`Register
`LiveIDead Indicator
`LIVE
`
`
`-
`Smutflifiw
`Fmsr Doc; PREV Dunc
`
`
`
`
`
`SEFFRCHDG
`
`|.HOME | SITE INDEX] SEARCH | eBUSlNESS | HELP | PRIVACY POLICY
`
`http://tn1sea1‘ch.uspto.go\*/bin/showfield?f:d0c8:state:4a8O+:h5u3yp.22.3
`
`10/ 12/20 16
`
`

`
`
`
`U‘3PTO Assignments on the Web
`
`Page I of 2
`
`
`
`United States Patent and Trademark Office
`
`Homelsite IndexISearchiGuides I ContactsIeBusiness|eBiz aiertsINews|He|ip
`
`
`
`Assignments on the Web > Trademark Query
`
`Trademark Assignment Abstract of Title
`
`Total Assignments: 4
`Filing Dt: 09/01/2011
`Serial #: 85413540
`Registrant: IROKO PROPERTIES INC.
`Mark: ZORVOLEX
`
`Assignment: 1
`
`Reg #: 4505759
`
`Reg. Dt: 04/01/2014
`
`Red/Frame: 5193 0406
`
`Recorded: 01/15/2014
`
`Pages: 6
`
`Conveyance: NUNC PRO TUNC ASSIGNMENT EFFECTIVE O6/30/2013
`
`Assignor: IROKO PHARMACEUTICALS LLC
`
`Assignee: IROKO PHARMACEUTICALS INC.
`GENEVA PLACE. WATERFRONT DRIVE
`TORTOLA, VIRGIN ISLANDS, BRITISH
`
`Correspondent: KEITH A. BARRI'|'|'
`P.O. BOX 1022
`
`MINNEAPOLIS, MN 55440-1022
`
`Domestic rep: KEITH A. BARRITT
`P.O. BOX 1022
`
`MINNEAPOLIS, MN 55440-1022
`
`Assignment: 2
`
`Exec Dt: 01/13/2014
`Entity Type: LIMITED LIABILITY
`COMPANY
`
`Citizenship: DELAWARE
`
`Entity Type: CORPORATION
`Citizenship: VIRGIN ISLANDS, BRITISH
`
`Ree]/Frame; £0
`
`Recorded: 01/17/2014
`
`Pages: 6
`
`Conveyance: NUNC PRO TUNC ASSIGNMENT EFFECTIVE 07/01/2013
`
`Assignor: IROKO PHARMACEUTICALS INC.
`
`Assignee: IROKO PROPERTIES INC.
`GENEVA PLACE, WATERFRONT DRIVE
`ROADTOWN, TORTOLA, VIRGIN ISLANDS, BRITISH
`
`Correspondent: KEITH A. BARRITT
`P.O. BOX 1022
`
`MINNEAPOLIS, MN 55440-1022
`
`Domestic rep: KEITH A. BARRITI
`P.O. BOX 1022
`
`MINNEAPOLIS, MN 55440-1022
`
`Assignment: 3
`
`Exec Dt: 01/13/2014
`Entity Type: CORPORATION
`Citizenship: VIRGIN ISLANDS, BRITISH
`
`Entity Type: CORPORATION
`citizenship: VIRGIN ISLANDS, BRITISH
`
`Pages: 8
`Recorded: 07/21/2015
`Reel/Frame; 5_$_0_[Q§_1.Z_
`CORRECTIVE ASSIGNMENT TO CORRECT THE ENTITY TYPE OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL
`Conveyance: 005195 FRAME 0802. ASSIGNOR(S) THE ENTITY TYPE OF THE ASSIGNEE IS A COMPANY OF THE BRITISH
`VIRGIN ISLAND. HEREBY CONFIRMS THE NUNC PRO TUNC ASSIGNMENT EFFECTIVE O7/01/2013.
`
`Assignor: IROKO PHARMACEUTICALS INC.
`
`Assignee: IROKO PROPERTIES INC.
`GENEVA PLACE WATERFRONT DRIVE
`
`Exec Dt: O1/13/2014
`Entity Type: CORPORATION
`Citizenship: VIRGIN ISLANDS, BRI"ISH
`
`Entity Type: COMPANY
`Citizenship: VIRGIN ISLANDS, BRI"ISH
`
`http://2IssIgI1IIIeI1ts.uspt0.gov/assIgIIIneIIts /q?db:tm&qt:sIIO&1“eeI: &II‘EI111€: &sII0:8...
`
`I0/ 12/20 16
`
`

`
`I ‘EPTO Assignments on the Web
`
`Page 2 of 2
`
`P.O. BOX 3469
`
`ROAD TOWN, TORTOLA, VIRGIN ISLANDS, BRITISH
`
`Correspondent: KEITH BARRITT
`P.O. BOX 1022
`
`MINNEAPOLIS, MN 55440-1022
`
`Domestic rep: KEITH BARRITF/FISH & RICHARDSON P.C.
`P.O. BOX 1022
`
`MINNEAPOLIS, MN 55440-1022
`
`Assignment: 4
`
`Reel/Frame: 5823/0375
`
`Recorded: 06/29/2016
`
`Pages: 27
`
`Conveyance: SECURITY INTEREST
`
`Assignors: IROKO PHARMACEUTICALS LLC
`
`IROKO PROPERTIES INC.
`
`IROKO PHARMACEUTICALS PUERTO RICO CORPORATION
`
`Assignee: CRG SERVICING LLC
`1000 MAIN STREET, SUITE 2500
`HOUSTON’ TEXAS 77002
`Correspondent: JENNIFER FITZPATRICK
`C/O COOLEY LLP
`4401 EASTGATE MALL
`
`SAN DIEGO, CA 92121
`
`Exec Dt: 06/27/2016
`Entity Type: LIMITED LIABILITY
`COMPANY
`
`Citizenship: DELAWARE
`Exec Dt: 06/27/2016
`
`Entity Type: CORPORATION
`Citizenship: VIRGIN ISLANDS, BRITISH
`Exec Dt: 06/27/2016
`
`Entity Type: CORPORATION
`Citizenship: PUERTO RICO
`
`Entity Type: LIMITED LIABILITY
`COMPANY
`CItlZel1Shlp: DELAWARE
`
`Search Results as of: 10/12/2016 11:27 AM
`If you have any comments or questions concerning the data displayed, contact PRD /Assignments at 571-272-3350. v.2.5
`Web interface last modified: July 25, 2014 v.2.5
`
`I
`
`.HOME I INDEXI SEARCH I eBUSlNESS I CONTACT US I PRIVACY STATEMENT
`
`http://assignments.usptogov/assignments/q?db:t1n&qt:sno&reeI:&fi‘ame:&sno: 8...
`
`10/ 12/20 16
`
`

`
`IBIT 2
`
`

`
`
`
`zoa'¢c»L£> "
`
`
`ff Lctyflassifiatterstzam
`
`Ta find out about nanstercidal anti-tnflammatory drugs (u\tSAEDs)—and tn team how Imko ¥’ha:macem§:ats, iLC has used Soéuwtatrix Fine Particte
`?er.h:w?.ogy“’ ta createa Leta/-Ease NSAIEJ treatment option for managing mile’ to moderate acute pain us’ ostaoarthritis pain—cE1ckthe5etinks:
`
`Re
`
`
`
`.
`
` iv»
`
`7 ‘$3
`
`
`
`IMPORTANT SAFETY INFGRMATIGN
`
`A11 nan-steraidai anti-inflammatory drugs (NSAit3s}, like ZORVULEX, itzctease the risk of heart attack or stroke that cat: iead to death. This rtsk may happen
`eariy in treatment arm may tncteate with irstreasing dates and ltanget use csf tiiidfis. Avciti taking NSA1Ds after 3 recent heart attack.
`
`£30 not take ZORVOLEK right before car after a heart surgery tailed a “ctaronaty artery bypass graft {CABG}.‘'